No difference in etanercept levels between responders and non-responders in patients with ankylosing spondylitis treated with 25 mg etanercept twice a week

被引：0
|
作者：
de Vries, M. K. [1 ]
Wolbink, G. J. [2 ]
Nurmohamed, M. T. [3 ]
Aarden, L. A. [4 ]
Stapel, S. O. [4 ]
Peters, M. J. L. [3 ]
van denderen, J. C. [3 ]
Dijkmans, B. A. C. [1 ]
van der Horst-Bruinsma, I. E. [1 ]
机构：
[1] VU Med Ctr, Amsterdam, Netherlands
[2] Sanquin Res, Amsterdam, Netherlands
[3] Jan van Breeman Inst, Amsterdam, Netherlands
[4] Sanquin Res, Amsterdam, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [1] Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis
    van der Heijde, D.
    Da Silva, J. C.
    Duougados, M.
    Geher, P.
    van der Horst-Bruinma, I.
    Juanola, X.
    Olivieri, I.
    Raeman, F.
    Settas, L.
    Sieper, J.
    Szechinski, J.
    Walker, D.
    Boussuge, M-P
    Wajdula, J. S.
    Paolozzi, L.
    Fatenejad, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) : 1572 - 1577
  • [2] Etanercept 25 mg/week is effective enough remission for ankylosing spondylitis among to maintain Korean patients
    Lee, Sang-Hoon
    Lee, Yeon-Ah
    Hong, Seung-Jae
    Yang, Hyung-In
    CLINICAL RHEUMATOLOGY, 2008, 27 (02) : 179 - 181
  • [3] Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients
    Sang-Hoon Lee
    Yeon-Ah Lee
    Seung-Jae Hong
    Hyung-In Yang
    Clinical Rheumatology, 2008, 27 : 179 - 181
  • [4] Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
    Emery, Paul
    Szumski, Annette
    Bukowski, Jack
    Bananis, Eustratios
    Marshall, Lisa
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S184 - S184
  • [5] Etanercept 50mg once/week sustains clinical improvement in patients with psoriasis transferring from 25 mg etanercept twice/week
    Serban, Anca
    Ortonne, Jean Paul
    Elewski, Boni
    Leonardi, Craig
    Jahreis, Angelika
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1819 - 1819
  • [6] Difference in Persistence Rates between Responders and Non-Responders to Mailed Questionnaires
    Geers, Harm C. J.
    Heerdink, Eibert R.
    Bouvy, Marcel L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 327 - 327
  • [7] BASELINE CHARACTERISTICS OF PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF RESPONDERS VS NON-RESPONDERS TO ETANERCEPT
    Gisondi, P.
    Girolomoni, G.
    de Vlam, K.
    Al Hammadi, A.
    Carneiro, S.
    Hsu, M. -A.
    Szumski, A.
    Jones, H.
    Gallo, G.
    Chhabra, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1174 - 1174
  • [8] Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
    Braun, J.
    McHugh, N.
    Singh, A.
    Wajdula, J. S.
    Sato, R.
    RHEUMATOLOGY, 2007, 46 (06) : 999 - 1004
  • [9] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation
    Martyn-Simmons, C. L.
    Green, L.
    Ash, G.
    Groves, R. W.
    Smith, C. H.
    Barker, J. N. W. N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (12) : 1394 - 1397
  • [10] Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept
    van Denderen, J. C.
    Blom, G. J.
    van der Horst-Bruinsma, I. E.
    Dijkmans, B. A. C.
    Nurmohamed, M. T.
    CLINICAL RHEUMATOLOGY, 2012, 31 (12) : 1677 - 1682
12345